Loading
A phase 3 trial testing SCTB14 in non-small-cell lung cancer, now recruiting.
A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT07362459, led by Sinocelltech, and recruiting on the registry. Official title: A Phase III, Randomised, Double-blind, Multicenter Clinical Study to Evaluate the Efficacy and Safety of SCTB14 Versus Pembrolizumab as First-Line Therapy in Patients With Driver Gene-Negative, TPS ≥10% Locally Advanced or Metastatic Non-Small Cell Lung Cancer. Planned enrolment is 246 participants (estimated). The study started in 2025-12-30 and primary completion is expected in 2027-07. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sinocelltech, Non-small-cell lung cancer.
Shares Sinocelltech, Non-small-cell lung cancer.
Shares Sinocelltech, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/